Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, BridgeBio Pharma Inc’s stock clocked out at $45.12, up 1.67% from its previous closing price of $44.38. In other words, the price has increased by $1.67 from its previous closing price. On the day, 2.59 million shares were traded. BBIO stock price reached its highest trading level at $45.13 during the session, while it also had its lowest trading level at $43.78.
Ratios:
To gain a deeper understanding of BBIO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.54 and its Current Ratio is at 4.57.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on June 17, 2025, initiated with a Outperform rating and assigned the stock a target price of $49.
On March 31, 2025, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 24 ’25 when MCCORMICK FRANK sold 100,000 shares for $44.23 per share. The transaction valued at 4,422,800 led to the insider holds 879,979 shares of the business.
DENIS VON KAEPPLER IRA ROLLOVE bought 1,891 shares of BBIO for $83,261 on Jun 26 ’25. On Jun 26 ’25, another insider, HANNAH VALANTINE & DENIS VON K, who serves as the spouse of bod / bod is joint o of the company, bought 1,542 shares for $44.01 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 8567430144 and an Enterprise Value of 9894797312. For the stock, the TTM Price-to-Sale (P/S) ratio is 67.24. Its current Enterprise Value per Revenue stands at 77.658 whereas that against EBITDA is -14.932.
Stock Price History:
The Beta on a monthly basis for BBIO is 1.13, which has changed by 0.78128695 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, BBIO has reached a high of $45.18, while it has fallen to a 52-week low of $21.72. The 50-Day Moving Average of the stock is 22.67%, while the 200-Day Moving Average is calculated to be 43.97%.
Shares Statistics:
It appears that BBIO traded 2.95M shares on average per day over the past three months and 3189220 shares per day over the past ten days. A total of 189.83M shares are outstanding, with a floating share count of 160.74M. Insiders hold about 15.35% of the company’s shares, while institutions hold 85.70% stake in the company. Shares short for BBIO as of 1749772800 were 21119414 with a Short Ratio of 7.15, compared to 1747267200 on 22397501. Therefore, it implies a Short% of Shares Outstanding of 21119414 and a Short% of Float of 18.75.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 4.0 analysts are actively evaluating the performance of BridgeBio Pharma Inc (BBIO) in the stock market.The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.24 and low estimates of -$0.84.
Analysts are recommending an EPS of between -$1.94 and -$2.86 for the fiscal current year, implying an average EPS of -$2.34. EPS for the following year is -$1.87, with 5.0 analysts recommending between -$1.01 and -$2.49.
Revenue Estimates
In the current quarter, 14 analysts expect revenue to total $101.48M. It ranges from a high estimate of $198.5M to a low estimate of $55M. As of the current estimate, BridgeBio Pharma Inc’s year-ago sales were $2.17MFor the next quarter, 14 analysts are estimating revenue of $93.18M. There is a high estimate of $137.72M for the next quarter, whereas the lowest estimate is $31.89M.
A total of 19 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $666M, while the lowest revenue estimate was $235.31M, resulting in an average revenue estimate of $436.25M. In the same quarter a year ago, actual revenue was $221.9MBased on 18 analysts’ estimates, the company’s revenue will be $737.84M in the next fiscal year. The high estimate is $1.88B and the low estimate is $370.29M.
